Best Practices In Risk Mitigation Presented By Catalent At Internal Audit Summit
Somerset, N.J. – September 15, 2014 — Charles Silvey, Vice President of Internal Audit and Finance Operations, Catalent Pharma Solutions, will moderate the Chief Audit Executive Workshop session at the upcoming Internal Audit Summit, to be hosted at the Radisson Blu Warwick Hotel on the 17th – 19th September, 2014 in Philadelphia, PA. Mr. Silvey will also be one of three panellists for a discussion of “Best Practices to Mitigate Risks and Identify Sustainable Strategies to Prepare for the Challenges of Tomorrow.”
Mr. Silvey’s session, on September 17th at 3pm, will discuss the common challenges and solutions faced by Chief Audit Executives and examine ways to coordinate and report to Boards of Directors, the implementation of an annual audit action plan, mitigating enterprise risk, and the implications and ownership of the updated Committee of Sponsoring Organizations of the Treadway Commission (COSO) framework.
Mr. Silvey joined Catalent in 2008 in his current role as Vice President of Internal Audit. In that time he has built the Internal Audit Department in its multiple functions overseeing internal controls, FCPA compliance, travel and expense management and ethics. Prior to this, Mr. Silvey has held positions at Jefferson Wells International, Cambrex Corporation and KPMG. He holds a bachelor’s degree in business from Monmouth University in West Long Branch, New Jersey.
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
For more information on the Internal Audit Summit, visit: http://www.cbinet.com/conference/PC14265#.U-nHCKOj0Z8 and to arrange a meeting with Mr. Silvey, contact Richard Kerns at richard@nepr.eu.
Media Contacts
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns
+44 (0) 161 728 5880
richard@nepr.eu
About Catalent
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at 27 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com